The role of tau and beta-amyloid in Alzheimer's: What we know and what's next?
Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the most common form of dementia1. It’s defined by memory loss, cognitive decline, and behavioral changes, affecting individuals, families, and healthcare systems significantly. The prevalence of Alzheimer's is considerably increasing, with projections indicating a rise in cases as the global population ages.
AD has a complex and varied etiology, influenced by aging, genetics, and environmental factors2. Our current understanding involves multiple hypotheses, including cholinergic, beta-amyloid, tau protein, inflammatory, oxidative stress, metal ion, glutamate excitotoxicity, microbiota-gut-brain axis, and abnormal autophagy3-9. Each hypothesis provides unique insights into the complex mechanisms driving Alzheimer's pathology, with tau protein and beta-amyloid standing out because of their substantial impact on neuronal function and health.
This dual focus on tau and beta-amyloid drives research to unravel their complex roles and develop new therapies.
Understanding the tau protein
What is tau?
Tau is a protein that typically stabilizes microtubules in neurons. These microtubules are essential for maintaining cell structure and facilitating intracellular transport. In a healthy brain, tau supports the proper functioning of neurons by ensuring the stability of these microtubules10.
Tau in AD
In AD, tau becomes abnormal through a process called hyperphosphorylation. This results in the formation of neurofibrillary tangles, which disrupt the normal function of neurons and contribute to cell death11.
Mechanisms of tau pathology
The accumulation of tau in AD is driven by several mechanisms, including increased activity of tau kinases, chronic inflammation, and cellular signaling imbalances. These factors cause tau to misfold and aggregate, forming tangles that impair neuronal function and communication12.
Current research on Tau
Recent studies have focused on understanding the molecular mechanisms behind tau pathology and developing therapies to target tau tangles. Researchers are exploring approaches, such as tau kinase inhibitors and immunotherapies, to prevent tau aggregation and promote the clearance of existing tangles13,14.
Understanding beta-amyloid
What is beta-amyloid?
Beta-amyloid is a peptide derived from the amyloid precursor protein (APP). In its normal function, beta-amyloid regulates synaptic activity and protects against oxidative stress15.
Beta-amyloid in AD
In AD, beta-amyloid accumulates and forms plaques between neurons. These plaques disrupt cell-to-cell communication and trigger inflammatory responses, leading to neuronal damage and cognitive decline2.
Mechanisms of beta-amyloid pathology
Factors such as genetic mutations, impaired clearance mechanisms, and interactions with other proteins influence the accumulation of beta-amyloid. These plaques interfere with synaptic function and contribute to the neurodegenerative processes seen in Alzheimer's16.
Current research on beta-amyloid
Research on beta-amyloid has led to the development of therapies aimed at reducing plaque formation and promoting its clearance. Recent advancements include anti-amyloid antibodies and small molecules inhibiting beta-secretase, an enzyme involved in production17.
Interaction between tau and beta-amyloid
Synergistic effects
Tau and beta-amyloid interact in a way that exacerbates each other's pathological effects. Beta-amyloid plaques can promote tau hyperphosphorylation, while tau tangles can enhance beta-amyloid toxicity, creating a vicious cycle that accelerates neurodegeneration18.
Combined impact on brain function
The combined presence of tau tangles and beta-amyloid plaques severely disrupts neural communication and brain function. This interaction leads to widespread synaptic loss, neuronal death, and significant cognitive impairment.
Diagnostic and therapeutic approaches
Current diagnostic methods
Diagnosing Alzheimer's involves detecting tau and beta-amyloid in the brain through imaging techniques like PET (positron emission tomography) scans and measuring their levels in cerebrospinal fluid. These methods help identify the presence and extent of protein accumulation19.
Blood tests are also a powerful tool for diagnosing this condition. These tests measure Alzheimer's-related proteins that can enter the bloodstream from the brain. For instance, researchers at Washington University and Lund University developed a test for MTBR-tau243, reflecting toxic tau aggregates and correlating with Alzheimer's severity20. Another test, PrecivityAD2, measures the ratio of beta-amyloid and p-tau217 (phosphorylated tau), achieving 88% to 92% accuracy in diagnosis21.
Therapeutic strategies
Existing treatments for AD target tau and beta-amyloid through medications that aim to reduce their aggregation and promote clearance. Lifestyle interventions, such as diet and exercise, also play a role in managing the disease22.
Emerging therapies
Promising new therapies are being developed, including vaccines and multi-target approaches that simultaneously address tau and beta-amyloid. Monoclonal antibodies are a powerful tool for AD researchand a promising therapeutic strategy that selectively targets crucial factors like beta-amyloid peptide, tau protein, and neuroinflammation. Clinical trials are also underway to test the efficacy of these innovative treatments2.
Future directions
Research trends
Future research on tau and beta-amyloid will likely focus on understanding their interactions and developing more effective therapies. Advances in imaging and biomarker identification will enhance early diagnosis and treatment. For more information about biomarker assays, check out our article on the future directions of Alzheimer’s our article on the future directions of Alzheimer’s.
Innovative approaches
Innovative approaches, such as gene editing and personalized medicine, hold potential for treating Alzheimer's. These strategies aim to target the underlying genetic and molecular mechanisms of the disease23.
Challenges and opportunities
Despite the progress, challenges remain in Alzheimer's research, including the complexity of the disease and the need for more effective treatments. However, ongoing research and collaboration offer opportunities for breakthroughs that could transform the management of Alzheimer's.
Alzheimer's imaging, simplified
Discover our solutions, comprising primary antibodies (chimeric, conjugated, and carrier-free), secondary antibodies, and dyes
References
1. Kumar, A., Sidhu, J., Lui, F., et al. Alzheimer Disease. [Updated 2024 Feb 12]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK499922/
2. Zhang, J., Zhang, Y., Wang, J., et al. Recent advances in Alzheimer’s disease: mechanisms, clinical trials and new drug development strategies. Sig Transduct Target Ther 9, 211 (2024).
3. Chen, Z.-R., et al. Role of cholinergic signaling in Alzheimer's disease. Molecules 27, 1816 (2022).
4. Kinney, J. W., et al. Inflammation as a central mechanism in Alzheimer's disease. Alzheimer's Dement. (N. Y.) 4, 575-590 (2018).
5. Markesbery, W. R. Oxidative stress hypothesis in Alzheimer's disease. Free Radic. Biol. Med. 23, 134-147 (1997).
6. Chen, L.-L., et al. The metal ion hypothesis of Alzheimer's disease and the anti-neuroinflammatory effect of metal chelators. Bioorg. Chem. 131, 106301 (2023).
7. Esposito, Z., et al. Amyloid β, glutamate, excitotoxicity in Alzheimer's disease: are we on the right track? CNS Neurosci. Ther. 19, 549-555 (2013).
8. Kowalski, K., Mulak, A. Brain-gut-microbiota axis in Alzheimer's disease. J. Neurogastroenterol. Motil. 25, 48-60 (2019).
9. Funderburk, S. F., et al. Cell "self-eating" (autophagy) mechanism in Alzheimer's disease. Mt. Sinai J. Med. 77, 59-68 (2010).
10. Barbier, P., et al. Role of tau as a microtubule-associated protein: structural and functional aspects. Front. Aging Neurosci. 11, 204 (2019).
11. Iqbal, K., et al. Tau in Alzheimer disease and related tauopathies. Curr. Alzheimer Res. 7, 656-664 (2010).
12. Brunello, C. A., et al. Mechanisms of secretion and spreading of pathological tau protein. Cell. Mol. Life Sci. 77, 1721-1744 (2020).
13. Congdon, E. E., et al. Tau-targeting therapies for Alzheimer disease: current status and future directions. Nat. Rev. Neurol. 19, 715-736 (2023).
14. Basheer, N., Smolek, T., Hassan, I., et al. Does modulation of tau hyperphosphorylation represent a reasonable therapeutic strategy for Alzheimer’s disease? From preclinical studies to the clinical trials. Mol. Psychiatry 28, 2197-2214 (2023).
15. Chen, G.-F., Xu, T., Yan, Y., et al. Amyloid beta: structure, biology and structure-based therapeutic development. Acta Pharmacol. Sin. 38, 1205-1235 (2017).
16. Rajmohan, R., Reddy, P. H. Amyloid-beta and phosphorylated tau accumulations cause abnormalities at synapses of Alzheimer's disease neurons. J. Alzheimer's Dis. 57, 975-999 (2017).
17. Zhao, Z., et al. Current anti-amyloid-β therapy for Alzheimer's disease treatment: from clinical research to nanomedicine. Int. J. Nanomed. 18, 7825-7845 (2023).
18. Azargoonjahromi, A. The duality of amyloid-β: its role in normal and Alzheimer’s disease states. Mol. Brain 17, 44 (2024).
19. Lee, J. C., et al. Diagnosis of Alzheimer's disease utilizing amyloid and tau as fluid biomarkers. Exp. Mol. Med. 51, 1-10 (2019).
20. Horie, K., Salvadó, G., Koppisetti, R.K. et al. Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer’s disease. Nat Med (2025).
21. Meyer, M. R., et al. Clinical validation of the PrecivityAD2 blood test: A mass spectrometry-based test with algorithm combining %p-tau217 and Aβ42/40 ratio to identify presence of brain amyloid. Alzheimers Dement 20, 3179–3192 (2024).
22. Yiannopoulou, K. G., Papageorgiou, S. G. Current and future treatments in Alzheimer disease: an update. J. Cent. Nerv. Syst. Dis. 12, 1179573520907397 (2020).
23. Arafah, A., et al. The future of precision medicine in the cure of Alzheimer's disease. Biomedicines 11, 335 (2023).